Preclinical Efficacy of the Combination of Met and Src Family Kinase Inhibitors in Triple-Negative Breast Cancer.

被引：0
|
作者：
Gartner, E. M. [1 ]
Kim, E. M. H. [1 ]
Choi, L. [1 ]
Boerner, J. [1 ]
机构：
[1] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P008-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD08-08
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ADAMs as new therapeutic targets for triple-negative breast cancer.
    Mullooly, M.
    McGowan, P. M.
    Sukor, S. U.
    Madden, S. F.
    McDermott, E.
    Crown, J.
    O'Donovan, N.
    Duffy, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Expression of novel immunotherapeutic targets in triple-negative breast cancer.
    Basu, Gargi Dan
    Ghazalpour, Anatole
    Gatalica, Zoran
    Anderson, Karen S.
    McCullough, Ann E.
    Spetzer, David B.
    Pockaj, Barbara A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Met and HGF inhibition in triple-negative breast cancer cell lines
    Gaule, Patricia Brid
    Collins, Denis
    Walsh, Naomi
    Duffy, Michael J.
    Crown, John
    O'Donovan, Norma
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] A role for receptor tyrosine kinase crosstalk in a Met-dependent model of triple-negative breast cancer
    Sung, Vanessa
    Knight, Jennifer F.
    Park, Morag
    [J]. MOLECULAR CANCER RESEARCH, 2013, 11
  • [45] Preclinical efficacy of targeting c-MET by ARQ197 in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer cell lines
    Sun, Y.
    Carlson, J. H.
    Lin, X.
    De, P. K.
    Williams, C.
    Hausman, S.
    Dey, N.
    Leyland-Jones, B. R.
    [J]. CANCER RESEARCH, 2016, 76
  • [46] Rational combination therapy against triple-negative breast cancer
    Al-Ejeh, F.
    Miranda, M.
    Simpson, P. T.
    Chenevix-Trench, G.
    Lakhani, S. R.
    Khanna, K. K.
    [J]. CANCER RESEARCH, 2012, 72
  • [47] Combination treatment with bromodomain and extra-terminal motif inhibitors in triple-negative breast cancer
    Schafer, Johanna M.
    Lehmann, Brian D.
    Redman, Lindsay N.
    Liu, Phillip
    Stubbs, Matthew
    Ruggeri, Bruce
    Scherle, Peggy
    Pietenpol, Jennifer A.
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [48] Development of novel combination therapy for triple-negative breast cancer
    Lee, H.
    Lee, K.
    Lee, J.
    Yoon, K.
    Mohammad, A. M.
    Park, H. S.
    Park, J. S.
    Lee, S. -T.
    Sohn, J.
    [J]. BREAST, 2019, 44 : S36 - S37
  • [49] Novel synergy of radiosensitizer prodrug IPdR with Aurora kinase inhibitors in triple-negative breast cancer
    Rampurwala, Murtuza M.
    Choudhary, Alka
    Burkard, Mark E.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [50] Identifying specific inhibitors of triple-negative breast cancer subtypes
    Robles, A. J.
    Cai, S.
    Du, L.
    Shaffer, C. V.
    Grkovic, T.
    Risinger, A. L.
    O'Keefe, B. R.
    Cichewicz, R. H.
    Mooberry, S. L.
    [J]. PLANTA MEDICA, 2016, 82
12345